Lansoprazole
Product Images NDC 70934-423

4 FDA label images from Denton Pharma, Inc. Dba Northwind Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Lansoprazole (NDC 70934-423). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Denton Pharma, Inc. Dba Northwind Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (70934 423 30 Rev A 08 19)

Label (70934 423 30   Rev A 08 19)
Lansoprazole Delayed-Release Capsules USP 30mg packaging label from Denton Pharma, Inc. DBA Northwind Pharmaceuticals. The label indicates 30 capsules per container, Rx only, with storage instructions to keep out of reach of children, store on original container, and protect from moisture. NDC number 70934-423-30 is displayed along with dosage and temperature information.*
FDA Label Image

Figure1 (Figure1)

Figure1 (Figure1)
A line graph showing the mean severity of day heartburn over a 60-day period for evaluable patients, comparing placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily. The y-axis represents mean severity of day heartburn from 0 (none) to 3 (severe), and the x-axis shows days from the start of treatment, illustrating the reduction in heartburn severity with Lansoprazole doses compared to placebo.*
FDA Label Image

Figure2 (Figure2)

Figure2 (Figure2)
A line chart showing the mean severity of night heartburn over approximately 60 days from the start of treatment for evaluable patients. The severity scale ranges from 0 (None) to 3 (Severe). Three lines represent placebo, Lansoprazole 15 mg once daily, and Lansoprazole 30 mg once daily, with severity decreasing over time, especially for the Lansoprazole treatments.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure diagram of Lansoprazole showing molecular connections including a benzimidazole ring, sulfoxide group, and substituted pyridine ring.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.